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Abstract
Introduction: Multipotent stromal cells (MSCs) are currently in clinical trials for a number of inflammatory diseases.
Recent studies have demonstrated the ability of MSCs to attenuate inflammation in rodent models of acute lung
injury (ALI) suggesting that MSCs may also be beneficial in treating ALI.
Methods: To better understand how human MSCs (hMSCs) may act in ALI, the lungs of immunocompetent mice
were exposed to lipopolysaccharide (LPS) and four hours later bone marrow derived hMSCs were delivered by
oropharyngeal aspiration (OA). The effect of hMSCs on lung injury was assessed by measuring the lung wet/dry
weight ratio and total protein in bronchoalveolar lavage (BAL) fluid 24 or 48 h after LPS. BAL fluid was also
analyzed for the presence of inflammatory cells and cytokine expression by multiplex immunoassay. Microarray
analysis of total RNA isolated from treated and untreated lungs was performed to elucidate the mechanism(s)
involved in hMSC modulation of lung inflammation.
Results: Administration of hMSCs significantly reduced the expression of pro-inflammatory cytokines, neutrophil counts
and total protein in bronchoalveolar lavage. There was a concomitant reduction in pulmonary edema. The anti-
inflammatory effects of hMSCs were not dependent on localization to the lung, as intraperitoneal administration of hMSCs
also attenuated LPS-induced inflammation in the lung. Microarray analysis revealed significant induction of tumor necrosis
factor (TNF)-a-induced protein 6 (TNFAIP6/TSG-6) expression by hMSCs 12 h after OA delivery to LPS-exposed lungs.
Knockdown of TSG-6 expression in hMSCs by RNA interference abrogated most of their anti-inflammatory effects. In
addition, intra-pulmonary delivery of recombinant human TSG-6 reduced LPS-induced inflammation in the lung.
Conclusions: These results show that hMSCs recapitulate the observed beneficial effects of rodent MSCs in animal
models of ALI and suggest that the anti-inflammatory properties of hMSCs in the lung are explained, at least in
part, by activation of hMSCs to secrete TSG-6.
Introduction
Acute lung injury (ALI) and its more severe manifesta-
tion, acute respiratory distress syndrome (ARDS), are
major complications in critically ill patients. ALI is a
syndrome of widespread lung inflammation and
increased pulmonary vascular permeability resulting in
pulmonary edema, hypoxia and may contribute to multi-
ple organ failure and death. ALI/ARDS is most com-
monly caused by sepsis, pneumonia, trauma or
aspiration of gastric contents. Despite improvements in
critical care and mechanical ventilation protocols, the
mortality rate for patients with ALI is still 30% to 40%
[1-3]. Multipotent stromal cells (MSCs), also known as
mesenchymal stem cells, have been proposed as a cellu-
lar therapy for ALI.
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ability to self-renew and undergo differentiation into
mesenchymal lineage cell types including bone, cartilage,
adipose tissue, muscle and tendon [4]. MSCs have been
isolated from the bone marrow and the connective tis-
sue of almost all organs including adipose, periosteum,
synovial fluid, muscle, hair follicles, root of deciduous
teeth, articular cartilage, placenta, dermis, umbilical
cord, Wharton’s jelly, lung, liver and spleen [4-6]. The
interest in MSCs as cellular therapy arises from numer-
ous in vivo studies showing that MSCs avoid allorecog-
nition, home to sites of injury, and suppress
inflammation as well as immune responses. In addition,
MSCs can be rapidly expanded in vitro while maintain-
ing their multipotent properties [7]. MSCs are currently
in clinical trials for treatment of a number of human
diseases including osteogenesis imperfecta, osteoarthri-
tis, graft-versus-host disease, multiple sclerosis, types 1
and 2 diabetes, Crohn’s disease, acute kidney injury,
acute myocardial infarction, ischemic heart failure, and
chronic obstructive pulmonary disease [8].
Intravenous or intra-alveolar administration of MSCs
modulates both the inflammatory process and tissue
remodeling in experimental models of ALI despite mini-
mal, if any, engraftment (reviewed in [9]). The mechan-
isms involved are poorly understood; however, increasing
data suggest that the protective effects of MSCs are lar-
gely mediated through production of paracrine mediators
[7,10]. Most of what is known about the therapeutic
function of MSCs comes from studies that employed
rodent MSCs. It has been suggested that the mechanisms
of MSC-meditated immunosuppression may be different
between rodent MSCs and human MSCs (hMSCs) in
some models [11] but not in others, including the experi-
mental allergic encephalomyelitis model for multiple
sclerosis [12,13]. Before proceeding to clinical trials, it is
critical to understand the mechanisms integral to the
beneficial effects of hMSCs in ALI so that the human
physiological response can be accurately predicted.
To elucidate the mechanisms involved in human MSC
modulation of inflammation in the lung, we used intra-
pulmonary delivery of E. coli endotoxin to immunocom-
petent mice, a well-characterized model of ALI. Here we
demonstrated that xenographic transplantation of
hMSCs suppress inflammation and lung injury. Taking
advantage of the cross-species nature of our experi-
ments, we employed human-specific gene arrays to iden-
tify potential anti-inflammatory factors expressed by
hMSCs in the injured lung. TNF-a-induced protein 6
(TNAIP6/TSG-6) was shown to be highly induced in
hMSCS in response to lung injury. Using RNA interfer-
ence, we demonstrated that the anti-inflammatory prop-
erties of hMSCs in the lung are explained, at least in
part, by activation of hMSCs to secrete TSG-6.
Materials and methods
Cell culture
Adult hMSCs from bone marrow were obtained from
the Center for the Preparation and Distribution of Adult
Stem Cells [14]. The center has supplied standardized
preparations of MSCs enriched for early progenitor cells
to over 350 laboratories under the auspices of a
National Institutes of Health/National Center for
Research Resources (NIH/NCRR) grant (P40 RR17447).
Vials of about 0.5 × 10
6 cells (passage 1 or 2) were
thawed, plated on two-stack culture chambers (Corning,
Lowell, MA, USA) in 100 ml/stack of complete culture
medium (CCM) at 150 cells/cm
2 density, and incubated
at 37°C in 5% CO2 for six to seven days until 70% con-
fluent. The CCM consisted of a-MEM (Invitrogen,
Gaithersburg, MD, USA) containing 17% FBS (lot-
selected for rapid growth of hMSCs; Atlanta Biologicals,
Lawrenceville, GA, USA); 100 units/ml of penicillin; 100
μg/ml of streptomycin; and 2 mM L-glutamine (Invitro-
gen). One day before cells were to be administered,
medium was changed to antibiotic-free CCM. hMSCs
were harvested with 0.25% trypsin/1 mM EDTA (Invi-
trogen) for 3 minutes at 37°C, washed with PBS (with-
out Ca
2+ and Mg
2+) by centrifugation at 480 × g for 10
minutes at room temperature, resuspended in PBS and
administered to mice. IMR-90 human lung fibroblasts
(HLFs) were obtained from the American Type Culture
Collection (ATCC, Rockville, MD, USA) and cultured
according to manufacturer’s instructions. HLFs were
used at passages 14 to 15 for all experiments.
Animal model of ALI
Animal care and all animal procedures were approved
by the Institutional Animal Care and Use Committee of
Tulane University. Eight- to-ten-week-old female BALB/
C mice (National Cancer Institute-Frederick, Frederick,
MD, USA) were treated with either 1 mg/kg lipopolysac-
charide (LPS, Sigma-Aldrich, St. Louis, MO, USA) from
Escherichia coli (serotype 0111:B4) in 100 μlP B So ra n
equal volume of PBS, as vehicle control, by oropharyn-
geal aspiration (OA) as previously described [15]. Briefly,
mice were anesthetized with 2% isoflurane vapor
(VetOne, Meridian, ID, USA) in oxygen and suspended
on a string by the cranial incisors. A droplet was placed
in the back of the throat while simultaneously holding
the tongue to block the swallow reflex and pinching the
nose, forcing the mouse to breathe through its mouth
and in the process aspirate the liquid. Four hours after
LPS exposure, hMSCs or HLFs (2.5 × 10
5/100 μlP B S )
were given by OA and 30 minutes later a second dose
of equal concentration was administered, for a total of 5
×1 0
5 cells. As the control, 200 μl PBS was delivered as
described above. Recombinant human TSG-6 protein
(rhTSG-6, R&D Systems, Minneapolis, MN, USA) was
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doses, 30 minutes apart, 1 h and 10 h after LPS delivery
to the lung. Mice were anesthetized with 80 mg/kg keta-
mine plus 8 mg/kg xylazine and euthanized by exsangui-
nation 24 or 48 h after LPS treatment. The right lung
was processed for bronchoalveolar lavage (BAL) and the
left lung was used for RNA isolation or histology. Dry/
wet weight measurements were performed on whole
lungs from a separate set of animals.
Histology
Lungs were perfused with 10% buffered formalin
(Sigma-Aldrich) at a pressure of 25 cm H2Of o r1 5t o
20 minutes, removed from the animal and placed in
fresh 10% neutral buffered formalin for 16 to 20 h at 4°
C prior to processing and embedding. Sections (4 μM)
from each sample were stained with hematoxylin and
eosin (H&E) for histopathological evaluation by two
independent experts blinded to the treatment. Whole
H&E-stained sections were digitally imaged using an
Aperio ScanScope (Aperio Technologies, Vista, CA,
USA). TIFF Images of whole lung sections were
acquired using the ImageScope program from Aperio.
Threshold analysis of whole lung sections, excluding
non-parenchymal structures (for example, large blood
vessels, airway structural elements, connective struc-
tures, and so on), was performed using the NIH ImageJ
program. Briefly, RGB color images were split into indi-
vidual color channels (RGB stack), and analyses were
performed using the green channel. The threshold was
then adjusted to the highest point that would highlight
all areas of the parenchyma while excluding background.
The threshold area of total parenchyma was measured
and recorded. Then, the threshold was reset to highlight
only areas of high pixel density which correlated with
lung damage (damage threshold) as determined by
microscopic regional image analysis (Supplemental Fig-
ure S1 in Additional file 1). Equal threshold values were
applied across groups to all images analyzed. Lung
injury index was calculated as the ratio of damaged area
relative to total parenchyma area and reported as fold
increase over control lung (PBS + PBS).
Bronchoalveolar lavage (BAL) and differential cell counts
Lung lavage was performed immediately after euthanasia
with five aliquots consisting of 600 μl of sterile PBS sup-
plemented with 0.4 mM EDTA and protease inhibitor
cocktail (Roche, Indianapolis, IN, USA). Aliquots were
centrifuged at 1,500 × g for five minutes at 4°C to sepa-
rate cells from supernatant. Supernatant from the first
aliquot was stored at -70°C for biochemical analysis and
cells from all aliquots were combined and counted using
a grid hemocytometer. Differential cell counts were per-
formed after cytocentrifugation and staining with a
modified Wright stain (Diff-Quik, Fisher Scientific, Pitts-
burgh, PA, USA) by counting 300 cells in each of three
different viewing fields.
Lung wet/dry weight ratio
Lungs were dissected immediately after euthanasia and
the wet weight was recorded. Lungs were then placed in
an incubator at 65°C for 72 h, and the dry weight was
determined.
Cytokine and protein measurements
Measurement of cytokines and chemokines in BAL fluid
was performed by multiplex immunoassay using Milli-
plex mouse cytokine/chemokine 22-plex kit (Millipore,
Billerica, MA, USA) following the manufacturer’s
instructions. MIP-2 and MCP-1 levels were measured
with mouse specific Quantikine CXCL2/MIP-2 and
CCL2/JE/MCP-1 immunoassays, respectively (R&D Sys-
tems). The quantification of mouse IL-6 was performed
with mouse IL-6 ELISA MAX™ Deluxe Set from BioLe-
gend (San Diego, CA, USA) according to the manufac-
turer’s instruction. Protein concentration was quantified
using the Micro BCA protein assay kit (Pierce, Rockford,
IL, USA).
RNA isolation and RT-PCR
Total RNA was obtained from lung tissue homogenized
in TriPure Isolation Reagent (Roche) and was purified
with the RNeasy mini kit (Qiagen, Valencia, CA, USA).
Total RNA concentration was measured using NanoDrop
spectrophotometer (Thermo Scientific Nanodrop, Nano-
drop Technologies, Wilmington, DE, USA) and quality
assessed by the 260/280 and 230/260 ratios. Reverse tran-
scription was carried out with 1 μgo ft o t a lR N Au s i n ga
First Strand cDNA Synthesis kit (Bio-Rad, Hercules, CA,
USA) following the instructions provided by the manu-
facturer. Quantitative real-time PCR (qRT-PCR) was per-
formed using a 40-cycle two-step PCR (95°C for 15 sec
followed by 60°C for 1 minute) with sequence-specific
primer pairs using the iCycler IQ real-time detection Sys-
tem (Bio-Rad). qRT-PCR for human TSG-6 and GAPDH
mRNA was performed using human-specific TSG-6 pri-
mers/probe [15] or human GAPDH Taq-Man Gene
Expression Assay (Hs00266705_g1, Applied Biosystems,
Foster City, CA, USA) and Taqman Universal PCR Mas-
ter Mix (Applied Biosystems) with 200 ng of cDNA. The
number of viable hMSCs in mouse lung at the time of
euthanasia was evaluated as a percentage of administered
hMSCs based on qRT-PCR results for human GAPDH
mRNA as previously described [16]. Human keratinocyte
growth factor (KGF) and interleukin 1 receptor antago-
nist (IL1RN) mRNA levels were assayed using Taq-Man
Gene Expression Assays Hs00384281_m1 and
Hs00893625_m1, respectively (Applied Biosystems). The
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analyzing RNA isolated from mouse lung and hMSCs in
each reaction.
Microarray analysis
RNA was isolated from whole lungs of LPS- (LPS +
hMSC) or PBS-exposed (PBS + hMSC) mice 12 h after
OA administration of 5 × 10
5 hMSCs. Control RNA
was isolated from LPS-exposed lung treated with PBS
(LPS + PBS). To establish baseline levels of gene
expression in hMSCs prior to delivery to the lung, 5 ×
10
5 hMSCs were added to LPS- (LPS + hMSCs in vitro
mix) or PBS- (PBS + hMSCs in vitro mix) exposed
mouse lung immediately prior to homogenization.
RNA extracts from samples containing hMSCs were
analyzed for human GAPDH mRNA by qRT-PCR to
estimate the amount of human RNA in each sample.
To allow comparisons between samples containing
both human and mouse RNA, RNA extracts were
diluted to contain equal levels of human RNA. The
adjusted RNA samples (approximately 3 μgo ft o t a l
RNA) were assayed on a human (HG-U133 Plus 2.0)
microarray (Affymetrix, Santa Clara, CA, USA). An ali-
quot of total RNA extracted from LPS-exposed lung
treated with PBS, equal in concentration to the
adjusted RNA sample from LPS-exposed lung treated
with hMSCs, was also included to detect cross-hybridi-
zation of mouse RNA to the human chip. The data
were analyzed using Partek Genomics Suite 6.5 (Partek
Inc., St. Louis, MO, USA) and filtered for cross-hybri-
dization (CV >0.5 and call >33%) as previously
described [16]. Values were expressed as fold changes
relative to the signal intensities of controls. For a
human gene to be considered significantly up-regulated
in the LPS + hMSC sample the expression in the
human array had to be at least two-fold higher than in
the 1) LPS + PBS sample, 2) PBS + hMSC sample, 3)
LPS + hMSC in vitro mix sample, and 4) PBS + hMSC
in vitro mix sample.
siRNA transfection
Target hMSCs for transfection were cultured in anti-
biotic-free CCM and harvested as described above.
About 1 × 10
6 hMSCs were resuspended in 100 μl
resuspension buffer R (Neon Transfection System,
Invitrogen, Carlsbad, CA, USA) with 1 μMs i R N Af o r
TSG-6 (sc-39819; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or control non-silencing siRNA (sc-
37007; Santa Cruz Biotechnology) and transfected in
100 μl Neon tip with Neon transfection system (Invi-
trogen) using two pulses (1,400 V input pulse voltage/
20 ms input pulse width). Transfected hMSCs were
plated on 10 cm
2 tissue culture dishes in 7.5 ml anti-
biotic-free CCM for 24 h.
Myeloperoxidase (MPO) activity
MPO activity in BAL fluid was measured by continually
monitoring the change in absorbance of MPO reactions
at 460 nm for a period of five minutes using the Synergy
HT multi-detection microplate reader (Bio-Tek Instru-
ments, Winooski, VT, USA). Assays were conducted at
25°C in a final volume of 100 μl. The reaction buffer
contained 50 mM potassium phosphate (pH 6.0),
0.0005% (volume/volume) H2O2 and 0.167 mg/ml o-dia-
nisidine dihydrochloride (Sigma-Aldrich, St. Louis, MO,
USA). MPO activity in BAL fluid was expressed in
units/min/ml using a standard curve with 0 to 0.625
units/ml human leukocyte myeloperoxidase (Sigma-
Aldrich).
Statistical analyses
Data are shown as mean ± SEM. Comparisons between
the two groups were made using unpaired, two-tailed
Student’s t tests. P < 0.05 was considered statistically
significant. To assess the likely contribution of Type 1
error due to multiple analyses performed in the multi-
plex immunoassays, we calculated P-values for the null
hypothesis based on the exact confidence intervals for
samples from the binomial distribution [17,18].
Results
To elucidate the role of hMSCs in ALI, the lungs of
immunocompetent mice were exposed to LPS and 4 h
later 5 × 10
5 hMSCs, or HLFs as control, were delivered
by OA. At 24 and 48 h after LPS, animals were eutha-
nized by exanguination and lungs processed either for
BAL, RNA extraction, histology or lung wet/dry weight
measurements to assess inflammation and lung injury.
All experiments were repeated at least two times with
six animals per group, except where indicated.
Effect of hMSCs on LPS-induced pulmonary edema and
microvascular permeability
Histological examination of LPS-exposed lungs at 48 h
showed widespread septal thickening and interstitial
neutrophil infiltration, as well as significant air-space
cellularity and exudation; all of which were decreased in
lungs treated with hMSCs (Figure 1a). The alveolitis
induced by LPS is patchy; therefore, we employed
threshold analysis of H&E stained lung sections to
quantify lung injury (Supplemental Figure S1 in Addi-
tional file 1). Lungs from mice exposed to LPS had a
lung injury index of 5.6, whereas lungs from mice trea-
ted with hMSCs after LPS-exposure had a significantly
lower lung injury index of 3.6 (P < 0.05) (Figure 1b).
Pulmonary edema and total protein in BAL fluid were
assessed 24 h and 48 h after LPS as measures of lung
injury and vascular leak. LPS-exposed mice displayed
substantial pulmonary edema as indicated by an
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ment with hMSCs significantly decreased the pulmonary
e d e m aa tb o t h2 4a n d4 8h( P <0 . 0 5 )( F i g u r e1 c ) .A
similar pattern was seen in the total protein concentra-
tions in BAL fluid (Figure 1d) consistent with a decrease
in microvascular permeability. Administration of control
HLFs had no effect on lung wet/dry weight ratio or BAL
fluid protein concentration (Figure 1c, d).
Effects of hMSCs on inflammation
The total cell number in the BAL fluid was increased
approximately 10-fold 24 h after LPS exposure (Figure
2a). This increase was largely due to infiltration of neu-
trophils, which comprised more than 90% of cells in the
BAL fluid (Figure 2b). Administration of hMSCs signifi-
cantly reduced the total number of neutrophils in the
BAL fluid from approximately 2.6 × 10
6 to 1.5 × 10
6.I n
contrast, delivery of an equal number of HLFs resulted
in a slight increase in total cells and neutrophils in BAL
fluid. Consistent with these findings, MPO, an enzyme
marker of neutrophilic infiltration, was significantly
lower (P < 0.0001) in BAL fluid from mice treated with
hMSCs and unchanged in BAL fluid from mice treated
with HLFs (Figure 2c). Since neutrophil counts in BAL
fluid were not significantly different from total cell
counts, we used total cell counts for subsequent
analyses.
Macrophage inflammatory protein (MIP-2) is a potent
chemoattractant for neutrophils. A previous study
showed that MIP-2 was increased after exposure of
lungs to LPS and mouse MSCs (mMSCs) decreased its
expression [19]. To determine if hMSCs decrease
expression of MIP-2, BAL fluid was analyzed by ELISA.
MIP-2 was undetectable in PBS-treated control mice
and increased to approximately 600 mg/ml in response
to LPS. Treatment with hMSCs, but not HLFs, resulted
in a significant decrease (P < 0.05) in MIP-2 levels (Fig-
ure 2d). To further characterize the effect of hMSCs on
the inflammatory response to LPS, the BAL fluid was
assayed for 22 additional cytokines/chemokines using a
Figure 1 hMSCs decrease LPS-induced lung injury in immunocompetent mice.B A L B / Cm i c ew e r et r e a t e dw i t hL P So rP B Sv i a
oropharyngeal aspiration (OA) and four hours later 5 × 10
5 hMSCs and HLFs or PBS as controls, were delivered by OA. Lung injury was assessed
24 and 48 h later. (a) Representative images of hematoxylin and eosin staining of lung sections demonstrate reduced exudation and cellularity in
hMSC treated lungs 48 h after LPS. (b) A lung injury index was quantified by threshold image analysis of whole lung sections and reported as
fold change over control (PBS + PBS). (c) Pulmonary edema as measured by lung wet/dry weight ratio was significantly reduced in hMSC treated
groups (n=7 to 8 per group). (d) Total protein in BALF was also reduced in the hMSC treated groups (n=4 to 6 per group). Data are
presented as mean ± SEM. *P < 0.05 compared with LPS + PBS treated mice; † P < 0.05 compared with LPS + HLF treated group, and ‡ P <
0.0007 versus mice treated with PBS + PBS.
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the 22 cytokines/chemokines were detectable in LPS-
exposed lungs and 12 were decreased by OA hMSCs
(Supplemental Table S1 in Additional file 2). Treatment
with hMSCs significantly decreased (P < 0.05) expression
of the proinflammatory cytokines IL-1a,I L - 1 b,I L - 6 ,I L -
17 and the proinflammatory chemokines IP-10, MCP-1,
MIP-1a and RANTES (Figure 3). G-CSF, a cytokine that
recruits and activates neutrophils, was also significantly
reduced by hMSC administration. TNF-a levels were not
affected by hMSC administration. Levels of IL-10, an
anti-inflammatory cytokine, were very low in the lungs of
LPS-exposed mice and were slightly increased in
response to hMSC administration. The calculated prob-
ability that the significant results we observed are due
only to Type I error is P < 0.0001. Moreover, indepen-
dent ELISAs for IL-6 and MCP-1 confirmed the accuracy
of the multiplex immunoassay and further showed that
HLFs had no effect on the levels of these cytokines (Sup-
plemental Figure S2 in Additional file 3).
To determine if the anti-inflammatory function of
hMSCs required direct contact with lung epithelium, 5
×1 0
5 hMSCs were delivered intravenously via the jugu-
lar vein (IV), intraperitoneally (IP), or by OA four hours
after LPS exposure. IV and OA administration resulted
in approximately equal numbers of hMSCs in the lung
one hour after delivery as evaluated by real-time RT-
PCR assays for live human cells (Figure 4a). In contrast,
no hMSCs could be detected in the lung after IP admin-
istration. Twenty-four hours after LPS exposure, animals
were euthanized and BAL carried out. Total cells in
BAL fluid were measured as an index of lung inflamma-
tion. Surprisingly, hMSCs significantly suppressed
inflammatory cell accumulation in the lung regardless of
the route of administration (Figure 4b). Total protein in
BAL fluid was significantly decreased by hMSCs deliv-
ered via OA or IV (Figure 4c). Although there was a
trend toward lower protein concentrations in BAL fluid
from animals receiving hMSCs IP, the differences were
not statistically significant. These findings support the
Figure 2 hMSCs attenuate LPS-induced lung inflammation in immunocompetent mice. BALB/C mice were treated with LPS or PBS via
oropharyngeal aspiration (OA) and four hours later 5 × 10
5 hMSCs and HLFs or PBS as controls, were delivered by OA. Differential cell counts,
myeloperoxidase (MPO) enzyme activity assay and ELISA for MIP-2 were performed on BAL fluid samples collected 24 h after LPS exposure. Total
cells (a), neutrophils (b), myeloperoxidase (MPO) activity (c) and MIP-2 levels (d) were all significantly reduced in LPS-exposed lungs after
treatment with hMSCs. HLFs had no effect on any of these measures. Data are expressed as mean ± SEM (n = 6 per group). *P < 0.05 compared
with LPS + PBS treated mice; † P < 0.05 compared with LPS + HLF treated mice, and ‡ P < 0.01 versus mice treated with PBS + PBS.
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hMSCs are mediated by paracrine factors.
hMSC upregulate expression of anti-inflammatory genes
in response to inflammation
To elucidate the mechanism(s) involved in hMSC mod-
ulation of lung inflammation, we performed microarray
analysis taking advantage of the cross-species nature of
our experiments. Human MSCs (5 × 10
5) were delivered
by OA to the lungs of mice four hours after treatment
with LPS or PBS. Total RNA was isolated from lungs 12
h later, a time at which assays for human GAPDH
mRNA indicated there were adequate amounts of
human mRNA for assays. To account for any differences
in the number of human cells among samples, the
amount of RNA analyzed from each sample was
Figure 3 Proinflammatory cytokine and chemokine expression is decreased by hMSC administration. Twenty-four hours after LPS
exposure, IL-1b, IL-6, IL-17, IP-10, MCP-1, MIP-1a and RANTES levels were measured by multiplex immunoassay in BAL fluid. Data are expressed
as mean ± SEM (n = 6 per group). *P < 0.05
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GAPDH mRNA as previously described [14]. The
adjusted RNA samples were analyzed on a human
microarray. After filtering for cross-hybridization with
mouse mRNA isolated from LPS + PBS lung, the data
indicated that 53 human genes were significantly upre-
gulated in the LPS-exposed lung compared to LPS +
hMSCs in vitro mix (Table 1, and Supplemental Figure
S3 in Additional file 4). Microarray data have been
deposited in Gene Expression Omnibus (accession num-
ber [GEO:GSE26567]).
One of the most highly upregulated human genes
identified in LPS-exposed lung encodes TNF-a-induced
protein 6 (TSG-6). TSG-6 is a potent anti-inflammatory
factor that was previously shown to play a role in intra-
venous hMSC improvement of myocardial infarction
[20,21]. Quantitative real-time RT-PCR (qRT-PCR) ana-
lysis of the same RNA samples used for microarray ana-
lysis demonstrated that hMSCs delivered to a PBS-
exposed lung upregulated their expression of TSG-6
mRNA approximately 100-fold over that in hMSCs
prior to delivery to the lung (PBS + hMSCs in vitro
mix). hMSCs delivered to LPS exposed lungs had even
higher levels (approximately 900-fold) of TSG-6 mRNA
expression (Figure 5a).
MSC expression of keratinocyte growth factor (KGF)
was previously shown to be essential for the therapeutic
effects of hMSCs in an ex vivo perfused lung model of
ALI [22]. No change in expression of KGF was detected
by the microarray analysis performed here. However,
qRT-PCR analysis of the RNA samples used for the
microarrays demonstrated an approximately 11-fold
induction in KGF expression in LPS + hMSCs exposed
lung. hMSCs delivered to a PBS-exposed lung did not
upregulate expression of KGF (Figure 5b).
Interleukin 1 receptor antagonist (IL-1RN), has been
implicated in the anti-inflammatory function of MSCs
[23]. IL-1RN mRNA levels were not detectable by qRT-
PCR in hMSCs prior to delivery to the lung (PBS +
hMSCs in vitro mix). However, hMSCs in the PBS-
exposed lungs expressed low levels of IL-1RN mRNA
(CT’s of 35 to 37) and hMSCs in LPS-exposed lungs
expressed approximately five-fold higher levels of IL-
1RN mRNA (Figure 5c).
Effect of TSG-6 on lung inflammation
To determine if TSG-6 mediates the therapeutic benefits
of hMSCs, cells were transiently transfected with TSG-6
siRNA by electroporation. TSG-6 siRNA significantly
knocked down basal levels of TSG-6 mRNA (Supplemen-
tal Figure S4 in Additional file 5) in hMSCs. Mock trans-
fection (No siRNA) or transfection with a non-silencing
(NS) siRNA resulted in slightly higher expression of
TSG-6 mRNA compared to hMSCs that were not trans-
fected (Supplemental Figure S4 in Additional file 5), sug-
gesting that the electroporation procedure itself induces
expression of TNFAIP6 in hMSCs. Equal amounts (5 ×
10
5) of hMSCs transfected with TSG-6 siRNA, NS siRNA
or mock transfected were administered to mice four
Figure 4 hMSCs suppress lung inflammation regardless of
route of administration. A total of 5 × 10
5 hMSCs were
administered OA, IV or IP four hours after LPS exposure. (a) The
percentage of delivered hMSCs in the lung after one hour was
measured by qRT-PCR of human GAPDH mRNA. (b) Total cell
counts in BAL fluid were significantly decreased by hMSC
administration via all three routes. (c) Total protein in BAL fluid was
slightly decreased by IP delivered MSCs and significantly decreased
by both OA and IV delivered MSCs. Data are expressed as mean ±
SEM (n = 5 to 6 per group), *P < 0.05 compared with LPS + PBS.
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processed for RNA extraction 24 h after LPS exposure.
qRT-PCR analysis showed that lungs receiving either
untransfected, mock transfected or NS siRNA transfected
hMSCs had significantly higher levels of human TSG-6
mRNA compared to lungs that received hMSCs trans-
fected with TSG-6 siRNA (Figure 6a). Importantly, LPS
induced increases in MIP-2 expression (Figure 6b), total
cell number (Figure 6c), MPO activity (Figure 6d) and
total protein (Figure 6e) in BAL fluid were all signifi-
cantly decreased by delivery of mock transfected or NS-
siRNA transfected hMSCs, but not TSG-6 siRNA trans-
fected hMSCs despite similar numbers of the different
transfected hMSCs in the lung 24 h after LPS exposure
(Figure 6f).
Analysis of BAL fluid from these mice using a Milliplex
mouse cytokine/chemokine panel further revealed that
TSG-6 mRNA knockdown abrogated most, but not all, of
the anti-inflammatory effects of hMSCs in the LPS-
exposed lung (Supplemental Table S2 in Additional file 6).
For example, TSG-6 siRNA had no effect on hMSC-
mediated suppression of IL-1a,I L - 1 b IL-7 and IL-13.
Consistent with these results, delivery of recombinant
human TSG-6 significantly decreased total cell numbers
(Figure 7a), and MPO activity (Figure 7b) in the BAL fluid
of LPS-exposed mice. These results suggest that TSG-6
mediates, in part, the immunosuppressive function of
hMSCs.
Discussion
Human MSCs attenuated LPS-induced lung inflamma-
tion and injury in immunocompetent mice. In response
to the pro-inflammatory environment in the LPS exposed
lung, hMSCs upregulated expression of a number of
genes. Some of these genes encode secreted factors with
known anti-inflammatory properties. One of the most
highly upregulated genes was TNFAIP6 that encodes
TSG-6. Knockdown of TSG-6 mRNA expression in
hMSCs abrogated most of their anti-inflammatory
effects. In addition, intra-pulmonary delivery of rhTSG-6
reduced LPS-induced inflammation in the lung. These
results suggest that hMSCs in the lung upregulated
expression of TNFAIP6 and the secreted TSG-6
decreased neutrophil accumulation and lung injury.
Previous studies have demonstrated the ability of mur-
ine MSCs to attenuate inflammation and lung injury in
rodent models of ALI [19,24,25]. Recently, the ability of
human MSCs to restore alveolar epithelial fluid trans-
port and lung fluid balance was demonstrated in a study
employing an ex vivo perfused human lung preparation
injured by E. coli endotoxin [22]. These studies have
ignited much interest in hMSCs as cellular therapy for
ALI. However, little is known about the mechanisms by
which MSCs modulate lung inflammation and repair.
The anti-inflammatory effects of mouse MSCs in the
lung have been associated with MSC secretion of inter-
leukin 1 receptor antagonist (IL1RN) [23] and TGF-b1
[26]. It is not clear how closely mMSCs resemble
hMSCs. Certainly these two populations of cells share
many features; however, there is some evidence that
mMSCs and hMSCs differ in their response to inflam-
matory cytokines. For example, Ren et al. showed in
vitro that inflammatory cytokines induce the expression
of indoleamine 2,3-dioxygenase (IDO), but not inducible
nitric oxide synthase (iNOS), in human MSCs, whereas
in mouse MSCs the opposite is true [11]. The goal of
our study was to investigate the mechanism(s) by which
human MSCs modulate inflammation in the lung.
Table 1 The top 10 transcripts of hMSCs, up-regulated in lung after OA delivery to LPS exposed mice
Gene name Gene
symbol
LPS + hMSCs vs LPS + hMSCs in
vitro mix
LPS + hMSCs vs PBS +
hMSCs




IFIT3 29 29 31
Tumor necrosis factor, alpha-induced
protein 6
TNFAIP6 25 3 24
Interleukin 8 IL8 19 10 23
Chemokine (C-X-C motif) ligand 6 CXCL6 18 18 17
Superoxide dismutase 2, mitochondrial SOD2 16 12 19
Chemokine (C-X-C motif) ligand 5 CXCL5 11 9 8
Spermidine/spermine N1-acetyltransferase 1 SAT1 10 7 14
Integrin-binding sialoprotein IBSP 76 6
Pregnancy-associated plasma protein A,
pappalysin 1
PAPPA 68 6
ATP-binding cassette, sub-family A, member 1 ABCA1 63 5
Shown are fold changes in mRNA levels assayed by microarray (Supplemental Figure S1 in Additional file 1). LPS + hMSCs is RNA extracted from LPS-exposed
lung 12 h after treatment with hMSCs; LPS + hMSCs in vitro mix is hMSCs added to lung tissue from LPS-exposed mouse immediately prior to RNA isolation; PBS
+ hMSCs is RNA extracted from PBS-exposed lung 12 h after treatment with hMSCs; LPS + PBS is RNA extracted from LPS-exposed lung 12 h after treatment with
PBS. hMSCs, human multipotent stromal cells; LPS, lipopolysaccharide; OA, oropharyngeal aspiration; PBS, phosphate buffered saline.
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Page 9 of 15For these studies we delivered human MSCs to immu-
nocompetent mice after intrapulmonary delivery of LPS,
a well-characterized mouse model of direct lung injury
that recapitulates many of the features of human ALI
including patchy intra-alveolar neutrophil infiltrates and
changes in epithelial permeability. A similar cross-spe-
cies strategy was used to elucidate the mechanism(s) by
which hMSCs improve heart function after myocardial
infarction [16]. In that study, hMSCs were delivered to
immunodeficient mice where they provided numerous
endogenous markers for the cells and caused no obvious
cross-species artifacts.
Our results demonstrated that hMSCs improved lung
histology and reduced pulmonary edema in immuno-
competent mice (Figure 1) similar to what has been
reported for syngeneic mMSCs in this model [19,24].
The improvement in lung injury was associated with a
decrease in proinflammatory cytokines and chemokines,
including some (IL-1a,I L - 1 b,M I P - 1 a a n dM I P - 2 )t h a t
function as chemoattractants and activators of neutro-
phils (Figures 2d and 3). Consistent with these results,
hMSC treated lungs had significantly fewer neutrophils,
the major mediator of lung injury in this model (Figure
2b). TNF-a levels in BAL fluid were not changed with
hMSC treatment and although there was a trend toward
increased IL-10 in BAL fluid the levels of IL-10 were
very low (Supplemental Table S1 in Additional file 2).
Administration of HLFs had no beneficial effects (Figure
2 and Supplemental Figure S2 in Additional file 3).
These results suggest that hMSCs protected the lung
primarily by preventing recruitment and/or activation of
neutrophils. In a study similar to ours, mouse MSCs
given four hours after LPS attenuated lung injury and
reduced the levels of TNF-a and MIP-2 in BAL fluid.
However, neutrophil influx or activation was not amelio-
rated [19]. The differences in the MSC effects on neu-
trophil influx may be explained by intrinsic differences
in MSCs from humans versus mice, but could also be
explained by differences in experimental conditions
between the studies, including strain of mice used, dose
of LPS and method of intra-pulmonary delivery.
The ability of human MSCs to attenuate lung inflam-
mation and injury in an immunocompetent mouse sug-
gests that the anti-inflammatory action of hMSCs in the
lung is non-major histocompatibility complex (MHC)-
restricted and further, that hMSCs are to some degree
immune privileged due to their immune modulatory
effects, as others have suggested [6]. These results sup-
port the use of allogeneic hMSCs in patients.
Our finding that hMSCs attenuated lung inflammation
when administered intravenously (Figure 4) was not sur-
prising since most of the injected cells are initially
trapped in the lung [16]. However, this is the first report
that MSCs delivered intraperitoneally attenuate inflam-
mation in the lung (Figure 4b, c). The hMSCs did not
travel to the lung after IP injection as indicated by the
absence of human GAPDH mRNA in the lung one hour
(Figure 4a) or six hours (data not shown) after injection.
The fate of the cells is currently under investigation.
The IP route of delivery was not as effective as OA and
IV routes in reducing LPS-induced lung injury. For
these experiments, we used a dose of hMSCs (5 × 10
5)
Figure 5 hMSCs upregulate expression of anti-inflammatory
genes in response to LPS-treated lung. Twelve hours after delivery
of 5 × 10
5 hMSCs to LPS- or PBS-exposed lungs, total RNA was
isolated from lungs and analyzed by quantitative RT-PCR for mRNA
expression of (a) human TNFAIP6,( b) human KGF,o r( c) human IL1RN.
Values represent fold increase over values obtained for LPS + hMSCs
in vitro mix. Data are shown as the mean ± SEM (n = 3 per group). *
P < 0.01 versus PBS + hMSCs; † P < 0.05 compared with PBS + PBS;
and ‡ P < 0.05 compared with LPS + PBS.
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Page 10 of 15Figure 6 Knockdown of TSG-6 mRNA in hMSCs reduces their anti-inflammatory effects. Mice were treated with LPS and four hours later 5
×1 0
5 hMSCs that were mock transfected (hMSCs/No siRNA), transfected with non-silencing siRNA (hMSCs/NS siRNA), or transfected with TSG-6
siRNA (hMSCs/TSG-6 siRNA) were delivered by OA. Human TSG-6 mRNA levels in the lung, as well as markers of inflammation and injury in BAL
fluid were assessed 24 hours later. (a) qRT-PCR analyses demonstrated significantly reduced levels of human TSG-6 mRNA in lungs of mice
treated with hMSCs/TSG-6 siRNA compared to those treated with hMSCs/No siRNA or hMSCs/NS siRNA. (b) MIP-2 concentrations (c) total cell
counts, and (d) MPO activity and (e) total protein concentration in the BAL fluid was attenuated in animals treated with hMSCs/No siRNA or
hMSCs/NS siRNA but not hMSCs/TSG-6 siRNA. (f) The percentage of delivered hMSCs in the lung at the time of human TSG-6 mRNA analysis
was determined by measuring human GAPDH mRNA levels and calculating the number of cells from a standard curve as previously described
[16]. Data are presented as means ± SEM (n = 6 per group). *P < 0.05 compared with LPS + PBS exposed mice; † P < 0.05 compared with mice
treated with hMSCs/No siRNA, and ‡ P < 0.05 versus mice treated with hMSCs/NS siRNA.
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possible that increasing the number of hMSCs adminis-
tered IP would provide better protection. Alternatively,
our results may suggest that the factor or factors
responsible for hMSC suppression of inflammation can
function systemically, whereas factors that enhance lung
repair may work best when delivered locally. Regardless,
these results strongly suggest that the beneficial proper-
ties of hMSCs are predominantly mediated through
secretion of factors that act in paracrine fashion.
The upregulation of TNFAIP6 by hMSCs in response
to the inflammatory milieu of the LPS-exposed lung
(Table 1) was of special interest because TSG-6 has pre-
viously been shown to play a role in the beneficial
effects of hMSCs [16]. TSG-6 is a 35 kDa, secreted pro-
tein produced by many cell types in response to TNF-a
and IL-1b [20,21]. hMSCs in the LPS-exposed lung
upregulated their TSG-6 mRNA expression more than
900-fold (Figure 5a). TSG-6 is composed mainly of con-
tiguous Link and CUB modules that interact with a
broad spectrum of glycosaminoglycans and proteins,
including HA, chondroitin 4-sulphate, dermatan sulfate,
heparan sulfate, heparin, inter-a-inhibitor, versican,
aggrecan, thrombospondin-1, and PTX3 [20]. The anti-
inflammatory properties of TSG-6 are well documented
and the mechanisms are beginning to be elucidated.
TSG-6 inhibits the inflammatory network of proteases
by increasing the inhibitory activity of inter-a-inhibitor
and bikunin [27]. TSG-6 also specifically binds and
sequesters hyaluronan fragments and has been shown to
be a potent inhibitor of neutrophil activation and migra-
tion, as well as tissue remodeling [28], through up-regu-
lation of Cox-2 and prostaglandin D2 expression
[28,29]. The precise mechanism(s) by which TSG-6
protects the lung from acute inflammation remains to
be determined.
Knockdown of TSG-6 mRNA expression in hMSCs
did not completely abrogate their anti-inflammatory
effects (Figure 6) suggesting that additional factors
expressed by hMSCs play a role in protecting the lung
from LPS-induced inflammation and injury. The
hMSCs used in our studies expressed high levels of
K G Fi nt h el u n g( F i g u r e5 b ) .L e eet al. showed in an
isolated, perfused human lung model challenged with
endotoxin, that secretion of KGF was essential for the
beneficial effect of hMSCs on alveolar epithelial fluid
transport [22]. In another study, Aguilar et al. [30]
showed that MSCs transfected with a tetracycline-
inducible KGF construct partially protected mice from
bleomycin-induced pulmonary fibrosis. The mechan-
isms underlying KGF’s protective effect in the lung are
not completely understood. KGF has plieotropic effects
on alveolar epithelial cells including; mitogenic acitiv-
ity, increased surfactant production [31], inhibition of
apoptosis [32], and increased transcription and/or
translation of the major sodium and chloride transport
proteins [33]. However, KGF is not known to have
direct anti-inflammatory activity. We postulate that
TSG-6 and KGF secreted by hMSCs cooperate to
attenuate lung injury by suppressing inflammation and
promoting lung repair respectively. MSCs secrete other
bioactive molecules such as IL1RN (Figure 5c), HGF,
EGF, TGF-b1, sTNFR1, Ang1 and STC-1 that may also
contribute to their immunomodulatory functions and
repair of injured lung [19,26,34-38]. Additional experi-
ments are required to determine the relative contribu-
tion of each of these factors to the beneficial effects of
hMSCs in the lung.
Figure 7 Recombinant human TSG-6 protein (rhTSG-6) attenuates LPS induced lung inflammation. A total of 25 μg of rhTSG-6 protein was
administered by OA 1 h and again 10 h after LPS-induced lung injury. Total cell counts (a) and MPO activity (b) in BAL fluid are significantly lower
in rhTSG-6 treated mouse lung. Data are shown as mean ± SEM (n = 5, LPS + PBS or n = 8 LPS + rhTSG-6). * P < 0.05 compared with LPS + PBS.
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hMSC expression of TSG-6 and other beneficial factors
such as KGF may improve their lung protective proper-
ties. One such strategy is to culture hMSCs as 3D aggre-
gates or as spheroids [39-41]. Recently it was shown that
hMSCs cultured in hanging drops formed spheroids and
expressed significantly higher levels of TSG-6 and STC-
1 compared to hMSCs cultured as monolayers. More-
over, hMSCs from dissociated spheroids were more
effective at suppressing inflammation in a mouse model
of peritonitis than were hMSCs cultured as adherent
monolayers [42]. Using a similar strategy we showed
that culture of hMSCs in spheroids increased their
expression of TSG-6, STC-1 and KGF (unpublished
data). Our finding that hMSCs delivered IP have benefi-
cial effects in the lung suggests the possibility of trans-
plantation of the intact spheroids. We are currently
comparing the therapeutic potential of traditionally cul-
tured hMSCs to that of spheroid hMSCs in our animal
model of ALI.
Conclusions
This study demonstrates that xenographic transplanta-
tion of human MSCs, by multiple routes, attenuates
inflammation and lung injury in an in vivo model of
acute lung injury. Identification of TSG-6 as a major
mediator of the beneficial effects of hMSCs in the lung
furthers our understanding of how hMSCs work and
supports the concept that the protective effects of MSCs
are largely mediated through production of paracrine
factors. It is unlikely that a single factor mediates the
beneficial effects of hMSCs. MSCs respond to their
environment by secreting a variety of factors referred to
as the secretome. Elucidation of the hMSC secretome
will likely provide strategies to improve the therapeutic
potential of hMSCs for treatment of lung injury.
In conclusion, our study provides important preclini-
cal data for potential clinical trials using allogeneic
hMSCs for treatment of ALI, a significant source of
morbidity and mortality in critically ill patients.
Additional material
Additional file 1: Supplemental Figure S1. Threshold image analysis of
LPS-induced lung injury treated with hMSCs. Damage fraction was
determined as the ratio of damaged area relative to total parenchyma
area. Injured areas determined by microscopic analysis appeared as
darkly staining areas macroscopically. Threshold analysis was performed
to measure total parenchyma area and injured area. A lung injury index
was determined as the percent damaged area relative to total
parenchyma area. (a, b, c) RGB images of whole H&E-stained sections.
Large blood vessels, airway elements, and connective structures have
been cleared and appear as background. (d, e, f) Threshold digital
highlighting of damaged areas. (g) Microscopic view of damaged area.
The scale bar represents 50 μm. The inset shows the whole section, and
the red box marks an area of lung injury and the blue box marks an area
with undetectable injury.
Additional file 2: Supplemental Table S1. Levels of mouse cytokine/
chemokine (pg/ml) in the BAL fluid of LPS-exposed lungs (24 h after
exposure) treated with hMSCs or PBS.
Additional file 3: Supplemental Figure S2. IL-6 and MCP-1 ELISA
analysis. BAL fluid from mice treated with PBS + PBS, LPS + PBS, LPS +
HLFs, LSP + hMSCs (same animals as in Figure 2) was analyzed by
individual ELISAs specific for (a) murine IL-6 or (b) murine MCP-1. The
levels of cytokines measured by the multiplex immunoassay and the
ELISAs were very similar. HLFs had no effect on the levels of either
cytokine. Data are expressed as mean ± SEM (n = 6 per group). *P < 0.05
compared with LPS + PBS treated mice; † P < 0.05 compared with LPS +
HLF treated mice, and ‡ P < 0.01 versus mice treated with PBS + PBS.
Additional File 4: Supplemental Figure S3. Heat map of human
microarray assays of mouse lungs. RNA was isolated from whole lungs of
LPS- (LPS + hMSC) or PBS-exposed (PBS + hMSC) mice 12 h after OA
administration of 5 × 10
5 hMSCs. RNA samples (approximately 3 μgo f
total RNA) were assayed on a human (HG-U133 Plus 2.0) microarray
(Affymetrix, Santa Clara, CA, USA). An aliquot of total RNA extracted from
LPS-exposed lung treated with PBS was also included to detect cross-
hybridization of mouse RNA to the human chip.
Additional File 5: Supplemental Figure S4. Efficient knockdown of
human TSG-6 mRNA by RNA interference. hMSCs were transfected with
TSG-6 siRNA (hMSCs/TSG-6 siRNA), control non-silencing siRNA (hMSCs/
NS siRNA), or mock transfected (hMSCs/No siRNA). Twenty-four hours
after transfection human TSG-6 mRNA was analyzed by qRT-PCR. Data
are presented as means ± SEM (n = 3). † P < 0.05 compared with mice
treated with hMSCs/No siRNA, and ‡ P < 0.05 versus mice treated with
hMSCs/NS siRNA.
Additional File 6: Supplemental Table S2. Levels of mouse cytokine/
chemokine (pg/ml) in the BAL fluid of LPS-exposed lungs (24 h after
exposure) treated with hMSCs transfected with TSG-6 siRNA (hMSCs/TSG-
6 siRNA), transfected with control non-silencing siRNA (hMSCs/NS siRNA),
or mock transfected (hMSCs/No siRNA).
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